Beyond cancer treatment, IL-2 holds promise for autoimmune diseases, inflammatory disorders, and other conditions. The FDA's approval of LYMPHIR (denileukin diftitox-cxdl) in the US in August 2024 for ...

Dublin, June 24, 2025 (GLOBE NEWSWIRE) -- The "Interleukin-2 Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering.

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) ...

In a new study, researchers identify biomarkers that may predict the efficacy of low-dose IL-2 (Ld-IL2) treatment in people with systemic lupus erythematosus (SLE). IL-2 stands for interleukin-2 – a ...

SUPRAME: A phase 3 trial comparing IMA203, an engineered T-cell receptor expressing T cell therapy (TCR-T) vs investigator’s choice in patients with previously treated advanced cutaneous melanoma.

HOUSTON - Coya Therapeutics, Inc. (NASDAQ: COYA), a $109.1 million market cap biotechnology company focusing on regulatory T ...

Phase 2 data presented at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting show deep and durable tumor regressions in heavily pre-treated melanoma patients, with a mild safety ...